INDP
Indaptus Therapeutics, Inc. NASDAQ Listed Aug 4, 2015$3.90
-13.33%
vs $4.50
Mkt Cap $3.8M
52w Low $1.06
21.9% of range
52w High $14.00
50d MA $2.48
200d MA $2.53
P/E (TTM)
—
EV/EBITDA
—
P/B
1.2x
Debt/Equity
0.0x
ROE
-661.5%
P/FCF
-0.3x
RSI (14)
62.20
ATR (14)
$1.07
Beta
0.99
50d MA
$2.48
200d MA
$2.53
Avg Volume
2.0M
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
3 Columbus Circle · New York City, NY 10019 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -4.36 | -3.10 | +28.9% | 1.96 | +1.5% | -4.6% | -5.9% | -3.4% | +1.8% | -1.7% | — |
| Nov 12, 2025 | AMC | -4.17 | -2.98 | +28.5% | 2.89 | -2.8% | +2.4% | -15.2% | -9.6% | +1.8% | -10.4% | — |
| Aug 13, 2025 | AMC | -9.24 | -9.09 | +1.6% | 8.44 | -5.8% | -7.5% | -8.8% | +9.0% | -4.3% | -0.1% | — |
| May 14, 2025 | AMC | -11.48 | -8.96 | +22.0% | 11.86 | -0.8% | -0.8% | +6.9% | -13.1% | +1.4% | -3.9% | — |
| Mar 13, 2025 | AMC | -0.41 | -0.38 | +7.3% | 22.59 | +1.3% | -0.2% | +0.9% | -0.3% | -4.9% | -1.9% | — |
| Nov 12, 2024 | AMC | -0.47 | -0.32 | +31.9% | 32.20 | +0.0% | +2.6% | -4.2% | -1.8% | -0.9% | -6.4% | — |
| Aug 12, 2024 | AMC | -0.54 | -0.47 | +13.0% | 47.88 | -0.6% | -2.3% | +0.6% | -0.6% | -1.2% | -0.6% | — |
| May 8, 2024 | AMC | -0.57 | -0.45 | +21.1% | 57.96 | +1.0% | +1.0% | +2.9% | -1.4% | +0.5% | +6.6% | — |
| Mar 13, 2024 | AMC | -0.54 | -0.47 | +13.0% | 56.00 | -3.0% | -4.5% | -2.1% | +3.2% | +6.2% | +13.2% | — |
| Nov 6, 2023 | AMC | -0.55 | -0.47 | +14.5% | 75.04 | +6.0% | -10.1% | +6.6% | -10.7% | +1.6% | -4.7% | — |
| Aug 14, 2023 | AMC | -0.58 | -0.39 | +32.8% | 69.44 | +0.8% | -9.7% | -3.1% | +10.1% | +1.7% | +0.0% | — |
| May 11, 2023 | AMC | -0.59 | -0.51 | +13.6% | 54.60 | +10.3% | +8.2% | -1.4% | -0.5% | -1.0% | +2.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 13 | Maxim Group | Maintains | Buy → Buy | — | $32.20 | $32.20 | +0.0% | +2.6% | -4.2% | -1.8% | -0.9% | -6.4% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.56 | $37.24 | +4.7% | +12.6% | +8.4% | -2.6% | -2.6% | +29.9% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.16 | $68.60 | -0.8% | +6.9% | -5.7% | -6.8% | -3.0% | -1.3% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $77.56 | $82.60 | +6.5% | -5.4% | +6.5% | -4.7% | -5.3% | -6.3% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $110.60 | $111.16 | +0.5% | -11.4% | -4.9% | -18.6% | -8.1% | +11.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.44 | $70.00 | +0.8% | -9.7% | -3.1% | +10.1% | +1.7% | +0.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.88 | $61.32 | -0.9% | +4.1% | +7.8% | -9.7% | -3.1% | +10.1% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.80 | $48.72 | -5.9% | -3.2% | +0.6% | +22.8% | +4.1% | +7.8% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.08 | $73.64 | +0.8% | -4.6% | -0.8% | -2.4% | -16.2% | +6.4% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.36 | $47.04 | +3.7% | +3.7% | -3.6% | +3.1% | +8.4% | +5.0% |
| Mar 8 | HC Wainwright & Co. | Maintains | Overweight → Overweight | — | $46.48 | $46.48 | +0.0% | -0.6% | -2.4% | +5.0% | -0.6% | -6.5% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.44 | $49.00 | +1.2% | -1.2% | +1.8% | -2.9% | +1.2% | +0.0% |
| Oct 19 | Maxim Group | Upgrade | Hold → Buy | — | $211.12 | $228.48 | +8.2% | +3.6% | +1.5% | -2.8% | -7.0% | +0.3% |
No insider trades available.
8-K · 2.02
!! High
Indaptus Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 15
8-K · 5.02
!!! Very High
Indaptus Therapeutics, Inc. -- 8-K 5.02: Executive Change
Indaptus Therapeutics (INDP) strengthens its board governance by appointing Tim Ruan as an independent director, effective April 22, 2026, potentially enhancing oversight and strategic guidance.
Apr 24
8-K · 5.02
!!! Very High
Indaptus Therapeutics, Inc. -- 8-K 5.02: Executive Change
Indaptus Therapeutics appointed Tim Ruan as an independent director effective April 22, 2026, strengthening board governance and oversight of the biopharmaceutical company's operations.
Apr 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
INDP appointed a new CFO, signaling potential strategic shifts in financial management that could affect capital allocation, investor communications, and operational efficiency going forward.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Avraham Ben-Tzvi's appointment to lead the Nominating Committee signals potential governance changes and future board composition shifts that could influence INDP's strategic direction and executive leadership.
Mar 24
8-K · 5.03
! Medium
Indaptus Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Indaptus Therapeutics increased authorized common shares to 1 billion and enabled written consent voting, providing greater capital-raising flexibility and streamlined governance for future transactions.
Feb 27
8-K · 1.01
! Medium
Indaptus Therapeutics, Inc. -- 8-K 1.01: Governance / Corporate
Indaptus Therapeutics secured voting commitments from major shareholders in exchange for reducing warrant exercise prices, consolidating control ahead of a February 26, 2026 shareholder meeting.
Feb 12
Institutional (13F) — Top 2
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 39,018 | $71K | New | Mar 2026 |
| 2 | Cwm, Llc | 2 | $4 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 8,110 | $17K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 506 | $1K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 462 | $966 | Feb 2026 |
Valuation
Market Cap
$3.8M
Enterprise Value
-$4.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
1.20x
P/S
—
P/FCF
-0.25x
EV/EBITDA
—
Shares Out
966K
Financials (TTM)
Revenue
$0
Net Income
-$18.9M
EBITDA
-$18.9M
Free Cash Flow
-$14.8M
Op Cash Flow
-$14.8M
EPS Basic
$-21.58
EPS Diluted
$-6.34
EPS Forward
$-6.34
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$9.3M
Total Liab.
$6.2M
Total Equity
$3.2M
Cash
$8.5M
LT Debt
$0
Book Value/Sh
$3.26
Debt/Equity
0.00x
Current Ratio
1.51
Quick Ratio
1.51
Returns & Growth
ROE
-661.5%
ROA
-223.9%
ROIC
-629.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
-1240.4%
Price Returns
2W
+0.6%
1M
-37.1%
3M
-14.6%
6M
-21.1%
12M
-81.4%
Technicals
52W High
$14.00
52W Low
$1.06
50d MA
$2.48
200d MA
$2.53
RSI (14)
62.20
ATR (14)
$1.07
Beta
0.99
Avg Volume
2.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:33pm
· Source: financialmodelingprep.com